Biotek-snakken — November 2025
-
the patient population for the overall survival analysis by expanding the sample size for that endpoint. With progression events accruing more slowly than anticipated, combined with the study being fully enrolled with sufficient follow-up on enrolled patients, we aligned with the FDA to conduct the PFS analysis on the entire randomized patient population. Following this change, we continue to have robust powering to show a benefit for PFS, and we remain highly confident that we will announce
-
Bioporto gennemfører fuldtegnet emission på 43 mio kr. https://proinvestor.com/investornyt/1383022/bioporto-gennemforer-fuldtegnet-emission-pa-43-mio-kr
-
Egetis: I mine øjne er det utroligt så længe Egetis har været handlet til så lav en pris. Men mon ikke der kommer andre boller på suppen med dagens fase 3 resultater.https://www.egetis.com/mfn_news/egetis-announces-positive-results-from-the-retriact-study-of-emcitate-tiratricol-in-mct8-deficiency/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind